Nausea Medicine Market Report 2026

The nausea medicine market size has grown strongly in recent years. It will grow from $3.22 billion in 2025 to $3.44 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to widespread use of chemotherapy-induced nausea drugs, rising prevalence of gastrointestinal disorders, increased travel-related motion sickness, expansion of hospital pharmacy networks, availability of otc antiemetic products.

The nausea medicine market size is expected to see strong growth in the next few years. It will grow to $4.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growth in cancer treatment volumes, increasing elderly population, rising demand for home-based nausea management, advancements in antiemetic drug development, expansion of online pharmacy channels. Major trends in the forecast period include increasing use of antiemetics in oncology care, growing demand for motion sickness medications, rising adoption of combination antiemetic therapies, expansion of over-the-counter nausea treatments, increasing focus on patient-friendly drug formulations.

The rising consumption of unhealthy diets is expected to drive the growth of the nausea medicine market in the coming years. Unhealthy diets are characterized by excessive intake of processed foods, sugars, unhealthy fats, and salt, coupled with a deficiency in essential nutrients like vitamins, minerals, and fiber. This trend is fueled by the convenience and affordability of processed and fast foods, which are more accessible than healthier options. Nausea medicines help manage health by alleviating nausea caused by gastrointestinal disorders, motion sickness, or medication side effects, reducing the urge to vomit and providing symptomatic relief. For instance, in April 2025, according to the American Journal of Preventive Medicine, a US-based organization, over 124,000 deaths in the United States each year are linked to consumption of ultra-processed foods. Consequently, the increase in unhealthy diets is driving the expansion of the nausea medicine market.

Major companies in the nausea medicine market are concentrating on developing innovative therapies, such as chemotherapy-induced nausea medications, to enhance patient outcomes and manage treatment-resistant cases. Chemotherapy-induced nausea medications are designed specifically to prevent or relieve nausea and vomiting caused by cancer chemotherapy, typically by targeting serotonin or neurokinin receptors in the brain. For example, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched AKYNZEO I.V., a ready-to-dilute intravenous injection combining fosnetupitant and palonosetron, aimed at preventing chemotherapy-induced nausea and vomiting (CINV). This single-dose 30-minute infusion provides protection against both acute and delayed phases of CINV, reducing the need for multiple antiemetic drugs, simplifying treatment, and improving patient compliance.

In January 2025, Knight Therapeutics, a Canada-based specialty pharmaceutical company, acquired Helsinn Healthcare SA for an undisclosed amount. Through this acquisition, Knight Therapeutics aims to expand access to and commercial reach of antiemetic therapies in Latin American markets, enhancing the distribution of treatments for chemotherapy-induced nausea and vomiting. Helsinn Healthcare SA is a Switzerland-based biopharmaceutical company specializing in nausea medications.

Major companies operating in the nausea medicine market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer Aktiengesellschaft, Merck & Co. Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Helsinn Healthcare SA, Mylan N.V., Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Zydus Lifesciences Limited, Amneal Pharmaceuticals Inc.

North America was the largest region in the nausea medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nausea medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nausea medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nausea medicine market by increasing costs of imported active pharmaceutical ingredients and finished drug formulations. These effects are most pronounced in oncology-related antiemetics and combination therapies, particularly across North America, Europe, and Asia-Pacific. Higher tariffs have led to pricing pressure in hospital and retail pharmacy channels. However, tariffs have encouraged domestic pharmaceutical manufacturing and improved supply chain resilience for essential nausea medications.

The nausea medicine market research report is one of a series of new reports that provides nausea medicine market statistics, including nausea medicine industry global market size, regional shares, competitors with a nausea medicine market share, detailed nausea medicine market segments, market trends and opportunities, and any further data you may need to thrive in the nausea medicine industry. This nausea medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nausea medicine refers to drugs designed to counteract the body’s emetic response by targeting specific receptors in the brain or gastrointestinal tract that trigger nausea and vomiting. These medicines are used to relieve or prevent nausea and vomiting caused by motion sickness, anesthesia, chemotherapy, gastrointestinal disorders, or pregnancy-related conditions.

The main types of nausea medicine include antagonists, cannabinoids, and others. Antagonists are substances, often drugs, that bind to receptors and block or reduce a biological response by preventing the action of other compounds, such as hormones or neurotransmitters. These medicines are used for various indications, including oncology, gastroesophageal reflux disease, motion sickness, and seasickness, and can be administered orally, via injection, transdermally, rectally, and through other routes. They are distributed through retail pharmacies, hospital pharmacies, online pharmacies, and other channels, serving end-users such as hospitals, homecare settings, ambulatory surgical centers, long-term care facilities, and individual consumers.

The nausea medicine market consists of sales of products including dopamine antagonists, ginger supplements, serotonin antagonists, anticholinergics, and antihistamines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.